Boyds expands Regulatory Affairs team to support growing demand

We are delighted to announce the appointment of two senior regulatory specialists, further expanding our ability to support life sciences companies as they navigate increasingly complex regulatory pathways.

The Expedited Investigational New Drug (IND) Pilot Program – The FDA’s Personal Transfer of Regulatory Obligations?

On 15 September 2026, the US FDA announced the final design of their Expedited IND Pilot Program.